Context Therapeutics Inc. Common Stock (CNTX) Stock Price, Quote & AI Analysis

Live CNTX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Context Therapeutics Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Context Therapeutics Inc. Common Stock (CNTX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

CNTX
Context Therapeutics Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
2.320000
High
2.360000
Low
2.240000
Volume
539,950
VWAP
-
Market Cap
$213,159,690.64
52W Range
$0.49 - $2.85
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 12, 2026 Q4
After Hours
EPS Estimate: $-0.1067
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Context Therapeutics Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Context Therapeutics Inc. Common Stock Overview

Company information

Company Overview

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Company Details
Market Cap
$206.73M
Shares Outstanding
91,879,200
Weighted Shares Outstanding
91,879,177
CEO
Martin A. Lehr
Address
2001 MARKET STREET, PHILADELPHIA, PA, 19103
Employees
9
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Context Therapeutics Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...